person · Reporting owner
Godshall Douglas Evan
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUNIC, INC.VTL · Entity 6306 | Director | September 19, 2018 | September 21, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUNIC, INC.
Report date September 19, 2018 · Filed September 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-09-19 transaction · row 1
1 source rowRow 1 · 2018-09-19 · Sale · Disposed 69,375 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.35. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.35. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EyePoint, Inc.
Report date June 22, 2021 · Filed June 23, 2021
Section 16 reporting ended · disclosed 2021-06-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,016 |
Reported balance
After 2021-06-22 transaction · row 1
1 source rowRow 1 · 2021-06-22 · Exercise / conversion · Acquired 2,500 · Balance 8,016 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-22 · Exercise / conversion · Acquired 2,500 · Balance 0 F1: The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021. F2: The Restricted Stock grant vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.13 · Expires 2023-06-22 | Direct | 11,000 |
Reported balance
After 2021-06-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-06-22 · Grant · Acquired 11,000 · Balance 11,000 F1: The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021. F3: The option to purchase vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021.
F2: The Restricted Stock grant vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.
F3: The option to purchase vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.
Shockwave Medical, Inc.
Report date May 31, 2024 · Filed May 31, 2024
Section 16 reporting ended · disclosed 2024-05-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 1
1 source rowRow 1 · 2024-05-31 · Disposition to issuer · Disposed 151,629 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2027-05-09 | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-31 · Disposition to issuer · Disposed 294,799 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2029-03-06 | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-31 · Disposition to issuer · Disposed 81,967 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. |
| Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-31 · Disposition to issuer · Disposed 100,810 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU subject to performance-based vesting conditions ("PSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such PSU (assuming attainment of (A) the actual level of performance for performance metrics for which the relevant performance period had been completed as of the Effective Time and (B) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period had not been completed as of the Effective Time) and (ii) the Merger Consideration. F5: (Continued from Footnote 4) The amount reported represents PSUs for which performance was deemed achieved assuming attainment of maximum level of performance. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"),
F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU subject to performance-based vesting conditions ("PSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such PSU (assuming attainment of (A) the actual level of performance for performance metrics for which the relevant performance period had been completed as of the Effective Time and (B) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period had not been completed as of the Effective Time) and (ii) the Merger Consideration.
F5: (Continued from Footnote 4) The amount reported represents PSUs for which performance was deemed achieved assuming attainment of maximum level of performance.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2022 Filed May 12, 2022 20:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 15,000 | $3.42 | $51,240.00 |
DisclosureSEC source: 0001209191-22-028684 · doc4.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. Read SEC document |
| April 25, 2022 Filed Nov 21, 2023 20:20 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 1,887 | $177.35 | $334,659.45 |
DisclosureSEC source: 0001209191-23-056402 · doc4.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,926 F1 · price: All reported securities were sold at a price of $177.35. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:30 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 230 | $158.13 | $36,369.90 |
DisclosureSEC source: 0001209191-22-012475 · doc4.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,813 Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:30 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 8,765 | $159.59 | $1,398,806.35 |
DisclosureSEC source: 0001209191-22-012475 · doc4.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,043 Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 20:58 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 70 | $145.55 | $10,188.50 |
DisclosureSEC source: 0001209191-22-010038 · doc4.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,808 Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 20:58 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 5,057 | $146.52 | $740,951.64 |
DisclosureSEC source: 0001209191-22-010038 · doc4.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,878 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 16:38 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 22,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006816 · doc4.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,104 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 16:38 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 4,831 | $155.03 | $748,949.93 |
DisclosureSEC source: 0001209191-22-006816 · doc4.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,025 Read SEC document |
| February 01, 2022 Filed Feb 15, 2022 20:49 UTC Amendment | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 22,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010027 · doc4a.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,935 Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 21:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 45,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001209191-21-066280 · doc4.xml · derivative · entry 10 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,799 Underlying: Common Stock · 45,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F10 · derivative.exercise_date: Twenty-Five percent of the shares subject to this option vested on 05/09/2018 and the balance of the shares vested in equal monthly installments thereafter for 36 months. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 21:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 500 | $212.02 | $106,010.00 |
DisclosureSEC source: 0001209191-21-066280 · doc4.xml · nonDerivative · entry 9 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,856 F9 · price: The reported securities were sold at a price of $212.02. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 21:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 300 | $210.14 | $63,042.00 |
DisclosureSEC source: 0001209191-21-066280 · doc4.xml · nonDerivative · entry 8 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,356 F8 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $210.09 to $210.15. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 21:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 3,780 | $209.60 | $792,288.00 |
DisclosureSEC source: 0001209191-21-066280 · doc4.xml · nonDerivative · entry 7 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,656 F7 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $209.07 to $210.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 21:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 6,232 | $208.55 | $1,299,683.60 |
DisclosureSEC source: 0001209191-21-066280 · doc4.xml · nonDerivative · entry 6 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,436 F6 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $208.06 to $209.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 21:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 13,703 | $207.37 | $2,841,591.11 |
DisclosureSEC source: 0001209191-21-066280 · doc4.xml · nonDerivative · entry 5 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,668 F5 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $207.01 to $207.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 21:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 14,827 | $206.59 | $3,063,109.93 |
DisclosureSEC source: 0001209191-21-066280 · doc4.xml · nonDerivative · entry 4 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,371 F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $206.01 to $207.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 21:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 3,958 | $205.71 | $814,200.18 |
DisclosureSEC source: 0001209191-21-066280 · doc4.xml · nonDerivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,198 F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $205.01 to $206.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 21:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,700 | $204.55 | $347,735.00 |
DisclosureSEC source: 0001209191-21-066280 · doc4.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,156 F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $204.01 to $204.70. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 21:00 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 45,000 | $3.42 | $153,720.00 |
DisclosureSEC source: 0001209191-21-066280 · doc4.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 17:01 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0000950103-21-012690 · dp156579_4-godshall.xml · derivative · entry 11 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,804 Underlying: Common Stock · 45,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F11 · derivative.exercise_date: Twenty-Five percent of the shares subject to this option vested on 5/9/18 and the balance of the shares are scheduled to vest in equal monthly installments thereafter for 36 months. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 17:01 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,100 | $191.73 | $210,903.00 |
DisclosureSEC source: 0000950103-21-012690 · dp156579_4-godshall.xml · nonDerivative · entry 10 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,856 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F10 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $191.35 to $192.13. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 17:01 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 3,500 | $190.66 | $667,310.00 |
DisclosureSEC source: 0000950103-21-012690 · dp156579_4-godshall.xml · nonDerivative · entry 9 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,956 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F9 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $190.31 to $191.15. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 17:01 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 7,882 | $189.67 | $1,494,978.94 |
DisclosureSEC source: 0000950103-21-012690 · dp156579_4-godshall.xml · nonDerivative · entry 8 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,456 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F8 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $189.28 to $190.21. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 17:01 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 7,212 | $188.84 | $1,361,914.08 |
DisclosureSEC source: 0000950103-21-012690 · dp156579_4-godshall.xml · nonDerivative · entry 7 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,338 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F7 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $188.27 to $189.25. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 17:01 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 12,274 | $187.69 | $2,303,707.06 |
DisclosureSEC source: 0000950103-21-012690 · dp156579_4-godshall.xml · nonDerivative · entry 6 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,550 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F6 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $187.26 to $188.23. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 17:01 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 8,273 | $186.86 | $1,545,892.78 |
DisclosureSEC source: 0000950103-21-012690 · dp156579_4-godshall.xml · nonDerivative · entry 5 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,824 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F5 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $186.21 to $187.16. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 17:01 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,359 | $185.52 | $252,121.68 |
DisclosureSEC source: 0000950103-21-012690 · dp156579_4-godshall.xml · nonDerivative · entry 4 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,097 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $185.18 to $186.17. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 17:01 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,700 | $184.72 | $314,024.00 |
DisclosureSEC source: 0000950103-21-012690 · dp156579_4-godshall.xml · nonDerivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,456 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $184.14 to $185.13. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 17:01 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,700 | $183.89 | $312,613.00 |
DisclosureSEC source: 0000950103-21-012690 · dp156579_4-godshall.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,156 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $183.07 to $184.06. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 17:01 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 45,000 | $3.42 | $153,720.00 |
DisclosureSEC source: 0000950103-21-012690 · dp156579_4-godshall.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 17:39 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-21-004459 · primarydocument.xml · derivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2023-06-22 F1 · date: The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021. F3 · derivative.exercise_date: The option to purchase vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 17:39 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004459 · primarydocument.xml · derivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021. F2 · derivative.exercise_date: The Restricted Stock grant vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021. F2 · derivative.expiration_date: The Restricted Stock grant vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 17:39 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004459 · primarydocument.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0000950103-21-007575 · dp151432_4-godshall.xml · derivative · entry 11 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,804 Underlying: Common Stock · 45,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F11 · derivative.exercise_date: Twenty-Five percent of the shares subject to this option vested on 5/9/18 and the balance of the shares are scheduled to vest in equal monthly installments thereafter for 36 months. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 512 | $162.14 | $83,015.68 |
DisclosureSEC source: 0000950103-21-007575 · dp151432_4-godshall.xml · nonDerivative · entry 10 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,856 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F10 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $161.99 to $162.35. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 6,470 | $161.12 | $1,042,446.40 |
DisclosureSEC source: 0000950103-21-007575 · dp151432_4-godshall.xml · nonDerivative · entry 9 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,368 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F9 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $160.75 to $161.65. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 21,033 | $160.17 | $3,368,855.61 |
DisclosureSEC source: 0000950103-21-007575 · dp151432_4-godshall.xml · nonDerivative · entry 8 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,838 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F8 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $159.73 to $160.70. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 6,485 | $159.23 | $1,032,606.55 |
DisclosureSEC source: 0000950103-21-007575 · dp151432_4-godshall.xml · nonDerivative · entry 7 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,871 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F7 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $158.72 to $159.70. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 5,061 | $158.37 | $801,510.57 |
DisclosureSEC source: 0000950103-21-007575 · dp151432_4-godshall.xml · nonDerivative · entry 6 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,356 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F6 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $157.71 to $158.70. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,038 | $156.84 | $162,799.92 |
DisclosureSEC source: 0000950103-21-007575 · dp151432_4-godshall.xml · nonDerivative · entry 5 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,417 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F5 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $156.69 to $157.28. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 302 | $155.79 | $47,048.58 |
DisclosureSEC source: 0000950103-21-007575 · dp151432_4-godshall.xml · nonDerivative · entry 4 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,455 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $155.37 to $155.97. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 2,799 | $154.70 | $433,005.30 |
DisclosureSEC source: 0000950103-21-007575 · dp151432_4-godshall.xml · nonDerivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,757 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $154.34 to $155.26. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,300 | $153.78 | $199,914.00 |
DisclosureSEC source: 0000950103-21-007575 · dp151432_4-godshall.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,556 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $153.18 to $154.10. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 45,000 | $3.42 | $153,720.00 |
DisclosureSEC source: 0000950103-21-007575 · dp151432_4-godshall.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 20:33 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 1,837 | $159.38 | $292,781.06 |
DisclosureSEC source: 0000950103-21-006063 · dp149941_4-godshall.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,856 Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 19:22 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 1,900 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001816 · primarydocument.xml · derivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested on the one-year anniversary of the grant date. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 19:22 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 1,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001816 · primarydocument.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:38 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0000950103-21-002733 · dp146439_4-godshall.xml · derivative · entry 10 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,804 Underlying: Common Stock · 45,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F9 · derivative.exercise_date: Twenty-Five percent of the shares subject to this option vested on 5/9/18 and the balance of the shares are scheduled to vest in equal monthly installments thereafter for 36 months. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:38 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Tax withholdingCommon Stock | 9,666 | $123.19 | $1,190,754.54 |
DisclosureSEC source: 0000950103-21-002733 · dp146439_4-godshall.xml · nonDerivative · entry 9 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,693 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:38 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 300 | $125.74 | $37,722.00 |
DisclosureSEC source: 0000950103-21-002733 · dp146439_4-godshall.xml · nonDerivative · entry 8 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,359 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/09/2020. F8 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $125.55 to $125.83. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.